Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

Improving attribution of adverse events in oncology clinical trials.

George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS.

Cancer Treat Rev. 2019 Jun;76:33-40. doi: 10.1016/j.ctrv.2019.04.004. Epub 2019 Apr 25. Review.

PMID:
31108240
2.

Bedrock nitrogen weathering stimulates biological nitrogen fixation.

Dynarski KA, Morford SL, Mitchell SA, Houlton BZ.

Ecology. 2019 Apr 21:e02741. doi: 10.1002/ecy.2741. [Epub ahead of print]

PMID:
31006111
3.

Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean.

Cho J, Yoon J, Kim Y, Oh D, Kim SJ, Ahn J, Suh GY, Nam SJ, Mitchell SA.

J Glob Oncol. 2019 Mar;5:1-10. doi: 10.1200/JGO.18.00193.

4.

Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Chung AE, Shoenbill K, Mitchell SA, Dueck AC, Schrag D, Bruner DW, Minasian LM, St Germain D, O'Mara AM, Baumgartner P, Rogak LJ, Abernethy AP, Griffin AC, Basch EM.

J Am Med Inform Assoc. 2019 Apr 1;26(4):276-285. doi: 10.1093/jamia/ocy169.

PMID:
30840079
6.

Effect of initial emergency room imaging choice on time to hip reduction and repeat imaging.

Walker MR, El Naga AN, Atassi OH, Perkins CH, Mitchell SA.

Injury. 2019 Mar;50(3):686-689. doi: 10.1016/j.injury.2019.01.032. Epub 2019 Jan 23.

PMID:
30712754
7.

Sampling Conditions for Conforming Voronoi Meshing by the VoroCrust Algorithm.

Abdelkader A, Bajaj CL, Ebeida MS, Mahmoud AH, Mitchell SA, Rushdi AA, Owens JD.

Lebniz Int Proc Inform. 2018 Jun;99. doi: 10.4230/LIPIcs.SoCG.2018.1.

8.

Evidence-based sizing of non-inferiority trials using decision models.

Lansdorp-Vogelaar I, Jagsi R, Jayasekera J, Stout NK, Mitchell SA, Feuer EJ.

BMC Med Res Methodol. 2019 Jan 7;19(1):3. doi: 10.1186/s12874-018-0643-2.

9.

Symptom Trajectories Are Associated With Co-occurring Symptoms During Chemotherapy for Breast Cancer.

Whisenant M, Wong B, Mitchell SA, Beck SL, Mooney K.

J Pain Symptom Manage. 2019 Feb;57(2):183-189. doi: 10.1016/j.jpainsymman.2018.11.010. Epub 2018 Nov 17.

PMID:
30453052
10.

Simplified lipid II-binding antimicrobial peptides: Design, synthesis and antimicrobial activity of bioconjugates of nisin rings A and B with pore-forming peptides.

Mitchell SA, Truscott F, Dickman R, Ward J, Tabor AB.

Bioorg Med Chem. 2018 Nov 15;26(21):5691-5700. doi: 10.1016/j.bmc.2018.10.015. Epub 2018 Oct 19.

11.

Outcomes of multidisciplinary treatment planning in US cancer care settings.

Prabhu Das I, Baker M, Altice C, Castro KM, Brandys B, Mitchell SA.

Cancer. 2018 Sep 15;124(18):3656-3667. doi: 10.1002/cncr.31394. Epub 2018 Sep 14. Review.

PMID:
30216477
12.

Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.

Basch E, Dueck AC, Rogak LJ, Mitchell SA, Minasian LM, Denicoff AM, Wind JK, Shaw MC, Heon N, Shi Q, Ginos B, Nelson GD, Meyers JP, Chang GJ, Mamon HJ, Weiser MR, Kolevska T, Reeve BB, Bruner DW, Schrag D.

J Clin Oncol. 2018 Sep 11:JCO2018788620. doi: 10.1200/JCO.2018.78.8620. [Epub ahead of print]

PMID:
30204536
13.

Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.

Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dirven L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Sloan J, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium (SISAQOL).

Lancet Oncol. 2018 Sep;19(9):e459-e469. doi: 10.1016/S1470-2045(18)30418-2.

14.

Masquelet Reconstruction for Posttraumatic Segmental Bone Defects in the Forearm.

Walker M, Sharareh B, Mitchell SA.

J Hand Surg Am. 2019 Apr;44(4):342.e1-342.e8. doi: 10.1016/j.jhsa.2018.07.003. Epub 2018 Aug 23.

PMID:
30146386
15.

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.

Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro JZ, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Sridhara R, Taphoorn MJB, Velikova G, Coens C.

Clin Trials. 2018 Dec;15(6):624-630. doi: 10.1177/1740774518795637. Epub 2018 Aug 24.

16.

Fatigue predicts impaired social adjustment in survivors of allogeneic hematopoietic cell transplantation (HCT).

Park J, Wehrlen L, Mitchell SA, Yang L, Bevans MF.

Support Care Cancer. 2019 Apr;27(4):1355-1363. doi: 10.1007/s00520-018-4411-y. Epub 2018 Aug 22.

PMID:
30136024
17.

Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology.

Sandler KA, Mitchell SA, Basch E, Raldow AC, Steinberg ML, Sharif J, Cook RR, Kupelian PA, McCloskey SA.

Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):44-52. doi: 10.1016/j.ijrobp.2018.04.048. Epub 2018 Jun 5.

PMID:
30102201
18.

Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients.

Kerep AZ, Broome J, Pirsl F, Curtis LM, Steinberg SM, Mitchell SA, Cowen EW, Pichard DC, Joe GO, Comis LE, Mays JW, Datiles MB 3rd, Stratton P, Zolton J, Berger A, Hendricks J, Kenyon M, Baruffaldi J, Titarenko I, Pulanic D, Baird K, Fowler DH, Gress RE, Pavletic SZ.

Bone Marrow Transplant. 2019 Jan;54(1):76-84. doi: 10.1038/s41409-018-0224-3. Epub 2018 Aug 8.

PMID:
30089900
19.

Policy brief on the nursing response to human trafficking.

Speck PM, Mitchell SA, Ekroos RA, Sanchez RV, Messias DKH.

Nurs Outlook. 2018 Jul - Aug;66(4):407-411. doi: 10.1016/j.outlook.2018.06.004. Epub 2018 Jun 28. No abstract available.

PMID:
30031546
20.

Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study.

Schoen MW, Basch E, Hudson LL, Chung AE, Mendoza TR, Mitchell SA, St Germain D, Baumgartner P, Sit L, Rogak LJ, Shouery M, Shalley E, Reeve BB, Fawzy MR, Bhavsar NA, Cleeland C, Schrag D, Dueck AC, Abernethy AP.

JMIR Hum Factors. 2018 Jul 16;5(3):e10070. doi: 10.2196/10070.

21.

Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.

Yu H, Truong H, Mitchell SA, Liclican A, Gosink JJ, Li W, Lin J, Feng JY, Jürgensmeier JM, Billin A, Xu R, Patterson S, Pagratis N.

SLAS Discov. 2018 Oct;23(9):919-929. doi: 10.1177/2472555218786165. Epub 2018 Jul 16.

22.

Anti-nerve growth factor does not change physical activity in normal young or aging mice but does increase activity in mice with skeletal pain.

Majuta LA, Mitchell SAT, Kuskowski MA, Mantyh PW.

Pain. 2018 Nov;159(11):2285-2295. doi: 10.1097/j.pain.0000000000001330.

PMID:
29994990
23.

New Insights in Understanding and Treating Bone Fracture Pain.

Mitchell SAT, Majuta LA, Mantyh PW.

Curr Osteoporos Rep. 2018 Aug;16(4):325-332. doi: 10.1007/s11914-018-0446-8. Review.

PMID:
29948820
24.

Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop.

Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger CS, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O'Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ.

Value Health. 2018 Jun;21(6):742-747. doi: 10.1016/j.jval.2017.09.009. Epub 2017 Nov 7.

25.

The Changing Sensory and Sympathetic Innervation of the Young, Adult and Aging Mouse Femur.

Chartier SR, Mitchell SAT, Majuta LA, Mantyh PW.

Neuroscience. 2018 Sep 1;387:178-190. doi: 10.1016/j.neuroscience.2018.01.047. Epub 2018 Feb 10.

26.

Mice with cancer-induced bone pain show a marked decline in day/night activity.

Majuta LA, Guedon JG, Mitchell SAT, Kuskowski MA, Mantyh PW.

Pain Rep. 2017 Aug 11;2(5):e614. doi: 10.1097/PR9.0000000000000614. eCollection 2017 Sep.

27.

Palliative care during and following allogeneic hematopoietic stem cell transplantation.

Mitchell SA.

Curr Opin Support Palliat Care. 2018 Mar;12(1):58-64. doi: 10.1097/SPC.0000000000000327. Review.

28.

Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections.

Kim J, Singh H, Ayalew K, Borror K, Campbell M, Johnson LL, Karesh A, Khin NA, Less JR, Menikoff J, Minasian L, Mitchell SA, Papadopoulos EJ, Piekarz RL, Prohaska KA, Thompson S, Sridhara R, Pazdur R, Kluetz PG.

Clin Cancer Res. 2018 Apr 15;24(8):1780-1784. doi: 10.1158/1078-0432.CCR-17-2555. Epub 2017 Dec 13.

29.

Treatment of Radial Head Fractures and Need for Revision Procedures at 1 and 2 Years.

Kupperman ES, Kupperman AI, Mitchell SA.

J Hand Surg Am. 2018 Mar;43(3):241-247. doi: 10.1016/j.jhsa.2017.10.022. Epub 2017 Nov 21.

PMID:
29169720
30.

Immunohistochemical localization of nerve growth factor, tropomyosin receptor kinase A, and p75 in the bone and articular cartilage of the mouse femur.

Chartier SR, Mitchell SA, Majuta LA, Mantyh PW.

Mol Pain. 2017 Jan-Dec;13:1744806917745465. doi: 10.1177/1744806917745465. Epub 2017 Nov 22.

31.

What Do "None," "Mild," "Moderate," "Severe," and "Very Severe" Mean to Patients With Cancer? Content Validity of PRO-CTCAE™ Response Scales.

Atkinson TM, Hay JL, Dueck AC, Mitchell SA, Mendoza TR, Rogak LJ, Minasian LM, Basch E.

J Pain Symptom Manage. 2018 Mar;55(3):e3-e6. doi: 10.1016/j.jpainsymman.2017.10.024. Epub 2017 Nov 10. No abstract available.

32.

Distinct Trajectories of Fatigue and Sleep Disturbance in Women Receiving Chemotherapy for Breast Cancer.

Whisenant M, Wong B, Mitchell SA, Beck SL, Mooney K.

Oncol Nurs Forum. 2017 Nov 1;44(6):739-750. doi: 10.1188/17.ONF.739-750.

33.

A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.

Burton HE, Mitchell SA, Watt M.

Pharmacoeconomics. 2017 Nov;35(11):1123-1140. doi: 10.1007/s40273-017-0540-2. Review.

34.

Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients.

Curtis LM, Pirsl F, Steinberg SM, Mitchell SA, Baird K, Cowen EW, Mays J, Buxbaum NP, Pichard DC, Im A, Avila D, Taylor T, Fowler DH, Gress RE, Pavletic SZ.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1980-1988. doi: 10.1016/j.bbmt.2017.08.005. Epub 2017 Aug 7.

35.

Leveraging Implementation Science to Improve Cancer Care Delivery and Patient Outcomes.

Mitchell SA, Chambers DA.

J Oncol Pract. 2017 Aug;13(8):523-529. doi: 10.1200/JOP.2017.024729. Epub 2017 Jul 10. No abstract available.

36.

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.

Wang X, Barbosa J, Blomgren P, Bremer MC, Chen J, Crawford JJ, Deng W, Dong L, Eigenbrot C, Gallion S, Hau J, Hu H, Johnson AR, Katewa A, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Mitchell SA, Ortwine DF, DiPaolo J, Reif K, Scheerens H, Schmitt A, Wong H, Xiong JM, Xu J, Zhao Z, Zhou F, Currie KS, Young WB.

ACS Med Chem Lett. 2017 May 3;8(6):608-613. doi: 10.1021/acsmedchemlett.7b00103. eCollection 2017 Jun 8.

37.

Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy.

Knoerl R, Gray E, Stricker C, Mitchell SA, Kippe K, Smith G, Dudley WN, Lavoie Smith EM.

Support Care Cancer. 2017 Nov;25(11):3437-3446. doi: 10.1007/s00520-017-3764-y. Epub 2017 Jun 2.

PMID:
28577231
38.

Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.

Mendoza TR, Dueck AC, Bennett AV, Mitchell SA, Reeve BB, Atkinson TM, Li Y, Castro KM, Denicoff A, Rogak LJ, Piekarz RL, Cleeland CS, Sloan JA, Schrag D, Basch E.

Clin Trials. 2017 Jun;14(3):255-263. doi: 10.1177/1740774517698645. Epub 2017 Mar 20.

39.

Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis.

Batson S, Mitchell SA, Windisch R, Damonte E, Munk VC, Reguart N.

Onco Targets Ther. 2017 May 5;10:2473-2482. doi: 10.2147/OTT.S134382. eCollection 2017.

40.

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

Basch E, Pugh SL, Dueck AC, Mitchell SA, Berk L, Fogh S, Rogak LJ, Gatewood M, Reeve BB, Mendoza TR, O'Mara AM, Denicoff AM, Minasian LM, Bennett AV, Setser A, Schrag D, Roof K, Moore JK, Gergel T, Stephans K, Rimner A, DeNittis A, Bruner DW.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):409-418. doi: 10.1016/j.ijrobp.2017.02.002. Epub 2017 Feb 10.

41.

Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries.

Badia JM, Casey AL, Petrosillo N, Hudson PM, Mitchell SA, Crosby C.

J Hosp Infect. 2017 May;96(1):1-15. doi: 10.1016/j.jhin.2017.03.004. Epub 2017 Mar 8. Review.

42.

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).

Kummar S, O'Sullivan Coyne G, Do KT, Turkbey B, Meltzer PS, Polley E, Choyke PL, Meehan R, Vilimas R, Horneffer Y, Juwara L, Lih A, Choudhary A, Mitchell SA, Helman LJ, Doroshow JH, Chen AP.

J Clin Oncol. 2017 May 10;35(14):1561-1569. doi: 10.1200/JCO.2016.71.1994. Epub 2017 Mar 28.

43.

Anti-nerve growth factor therapy increases spontaneous day/night activity in mice with orthopedic surgery-induced pain.

Majuta LA, Guedon JG, Mitchell SA, Ossipov MH, Mantyh PW.

Pain. 2017 Apr;158(4):605-617. doi: 10.1097/j.pain.0000000000000799.

44.

Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients.

Baeksted C, Pappot H, Nissen A, Hjollund NH, Mitchell SA, Basch E, Bidstrup PE, Dalton SO, Johansen C.

J Patient Rep Outcomes. 2017;1(1):1. doi: 10.1186/s41687-017-0005-6. Epub 2017 Sep 12.

46.

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards.

Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro J, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJB, Velikova G, Coens C; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium.

Lancet Oncol. 2016 Nov;17(11):e510-e514. doi: 10.1016/S1470-2045(16)30510-1. Epub 2016 Oct 18. Review.

47.

Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).

Hagelstein V, Ortland I, Wilmer A, Mitchell SA, Jaehde U.

Ann Oncol. 2016 Dec;27(12):2294-2299. doi: 10.1093/annonc/mdw422. Epub 2016 Sep 28.

48.

Correction: Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.

Cohen AT, Hamilton M, Bird A, Mitchell SA, Li X, Horblyuk R, Batson S.

PLoS One. 2016 Sep 15;11(9):e0163386. doi: 10.1371/journal.pone.0163386. eCollection 2016.

49.

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report.

Shaw BE, Hahn T, Martin PJ, Mitchell SA, Petersdorf EW, Armstrong GT, Shelburne N, Storer BE, Bhatia S.

Biol Blood Marrow Transplant. 2017 Jan;23(1):10-23. doi: 10.1016/j.bbmt.2016.08.018. Epub 2016 Aug 30. Review.

50.

Disk Density Tuning of a Maximal Random Packing.

Ebeida MS, Rushdi AA, Awad MA, Mahmoud AH, Yan DM, English SA, Owens JD, Bajaj CL, Mitchell SA.

Comput Graph Forum. 2016 Aug;35(5):259-269. Epub 2016 Aug 15.

Supplemental Content

Loading ...
Support Center